Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series
2007

Nifurtimox and Eflornithine for Sleeping Sickness

Sample size: 31 publication Evidence: moderate

Author Information

Author(s): Francesco Checchi, Patrice Piola, Harriet Ayikoru, Florence Thomas, Dominique Legros, Gerardo Priotto

Primary Institution: Epicentre, Paris, France

Hypothesis

Can the combination of nifurtimox and eflornithine effectively treat late-stage sleeping sickness?

Conclusion

The combination of nifurtimox and eflornithine shows promising efficacy and safety for treating late-stage sleeping sickness.

Supporting Evidence

  • All 31 patients were discharged alive.
  • No treatment-related deaths were reported.
  • Efficacy ranged from 90.3% to 100.0% based on different analysis methods.
  • Neutropenia was a common adverse event, affecting 9 out of 31 patients.

Takeaway

Doctors tested a new medicine mix to help sick people in Africa, and it worked really well without causing many problems.

Methodology

Patients received a combination of nifurtimox and eflornithine, and their health was monitored for 24 months.

Potential Biases

Possible ascertainment bias regarding mild adverse events.

Limitations

The study lacked a comparator group and had a small sample size.

Participant Demographics

{"female_percentage":48.4,"mean_age":23.9,"mean_weight":44.8,"mean_body_mass_index":18.2}

Digital Object Identifier (DOI)

10.1371/journal.pntd.0000064

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication